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In 2009, we identified a novel mycobacterial 
species, Mycobacterium riyadhense, which was 
isolated from a patient in Riyadh, Saudi Arabia [1]. In 
2012, there were two new reports on three additional 
cases in Korea, Bahrain and France, caused by the 
same bacteria, thus showing its emerging potential 
worldwide [2-3]. In these three cases, M. riyadhense 
was isolated from broncho-alveolar lavage and 
sputum, and associated with disease. All of the 
reported patients received regular anti-tuberculosis 
treatment until the causative agent was properly 
identified; for some, these results became available 
one year after presentation [3]. 
M. riyadhense is a slow-growing Mycobacterium 
which produces rough, white colonies after four weeks 
of incubation at 36ºC. Biochemical properties include 
(i) nitrate reduction, Tween 80 hydrolysis, 
arylsulfatase, and urease activities; (ii) absence of 
niacin accumulation, heat stable catalase and tellurite 
reduction; (iii) no growth on MacConkey agar; (iv) 
negative tolerance to p-nitrobenzoic acid, 
hydroxylamine and oleic acid; and (v) tolerance to 
thiophene-2-carboxylic hydrase, thiocetazone and 
isoniazid.  
Phylogenetically, M. riyadhense is very close to 
M. szulgai and contains the region of difference-1 
(RD1) with virulent factors (esat-6 and cfp-10 genes), 
also present in M. tuberculosis. The 16S rRNA, hsp65 
and rpoB genes and the 16S-23S internal transcribed 
spacer sequences are unique [1]. The emerging reports 
on diseases mimicking tuberculosis (TB), but caused 
by M. riyadhense, emphasize the need for proper 
identification of mycobacteria in the diagnosis of 
mycobacterial diseases. It is conceivable that 
nontuberculous mycobacterial (NTM) diseases are 
more frequent than previously assumed and 
misdiagnosed as TB. This is especially a problem for 
bacteria such as M. riyadhense with its ability to cause 
pulmonary and extra pulmonary, TB-like disease in 
apparently immunocompetent individuals and which 
are actually identified as M. tuberculosis by some 
popular commercial identification assays such as 
GenoType MTBC/CM [1,3-4].  
Proper distinction of TB and NTM disease is of the 
utmost importance, because this has profound 
consequences for treatment. Standardized TB 
treatment is insufficient for NTM, including M. 
riyadhense; currently reported cases followed at least 
nine months of first-line drug therapy to attain a cure 
[1-3]. The problem with the identification of newly 
recognized mycobacteria such as M. riyadhense is that 
there are no commercially available kits to facilitate a 
timely and accurate diagnosis; only DNA sequencing 
will offer definitive identification. The currently 
available identification assays focus on the most 
frequently isolated species and lack the flexibility to 
adjust to new and emerging species. If M. riyadhense 
infections are becoming more associated with serious 
disease, it would be important to include testing for 
these bacteria in commercial identification kits. Only 
frequent testing for M. riyadhense will provide an 
accurate assessment of its true prevalence. This 
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species may be of specific interest because it harbours 
an ESX-1 system, a well-known virulence factor of M. 
tuberculosis that is also functional in NTM, at least in 
M. kansasii and M. szulgai [5]. 
More cases of TB than currently assumed may 
actually represent NTM disease, caused by species 
such as M. riyadhense; therefore, more sophisticated 
identification tools, including DNA sequencing and 
the inclusion of newly emerging species into 
commercial identification kits, are imperative research 
goals. 
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